CV-01
Target
Indication
Hit
Lead
Tox
Non-Clinical
Ph 1
Detail
Keap1-Nrf2
Alzheimer
Parkinson
CKD
In Progress
Target
Indication
Ph 1
Keap1-Nrf2
Alzheimer
Parkinson
CKD
In Progress
Keap1 mediated Nrf2 Activation for neuroprotection and inhibit neuroinflammation
CV-01’s Reversibility and Selectivity
- We are developing a first-in-class candidate that targets the Keap1/Nrf2 pathway
- Our differentiation lies in its highly selective and unique target-drug binding mechanism
- Potential to expand its indications to include chronic inflammatory diseases like nephritis and colitis
